Form 13-F position report

BRAINSTORM CELL THERAPEUTICS I

Reported by STATE STREET CORPORATION

BCLI CUSIP 10501E201 Manager CIK 0000093751

Reported 0 shares, down 117,260 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 19 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 286000
2021-12-31 347000
2022-03-31 323000
2022-06-30 265000
2022-09-30 425000
2022-12-31 157538
2023-03-31 316998
2023-06-30 197884
2023-09-30 19222
2023-12-31 26224
2024-03-31 54245
2024-06-30 39693
2024-09-30 27005
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for BRAINSTORM CELL THERAPEUTICS I held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -117,260 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 117,260 0 (0.0%) < 0.01% $27,005 2024-11-14
Q2 2024 Added 117,260 +21,200 (22.1%) < 0.01% $39,693 2024-08-14
Q1 2024 Unchanged 96,060 0 (0.0%) < 0.01% $54,245 2024-05-15
Q4 2023 Unchanged 96,060 0 (0.0%) < 0.01% $26,224 2024-02-14
Q3 2023 Unchanged 96,060 0 (0.0%) < 0.01% $19,222 2023-11-14
Q2 2023 Unchanged 96,060 0 (0.0%) < 0.01% $197,884 2023-08-14
Q1 2023 Unchanged 96,060 0 (0.0%) < 0.01% $316,998 2023-05-15
Q4 2022 Unchanged 96,060 0 (0.0%) < 0.01% $157,538 2023-02-14
Q3 2022 Unchanged 96,060 0 (0.0%) < 0.01% $425,000 2022-11-15
Q2 2022 Unchanged 96,060 0 (0.0%) < 0.01% $265,000 2022-08-15
Q1 2022 Added 96,060 +9,357 (10.8%) < 0.01% $323,000 2022-05-16
Q4 2021 Unchanged 86,703 0 (0.0%) < 0.01% $347,000 2022-02-14
Q3 2021 Unchanged 86,703 0 (0.0%) < 0.01% $286,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

35 managers reported BRAINSTORM CELL THERAPEUTICS I for Q4 2024.

Managers reporting BRAINSTORM CELL THERAPEUTICS I in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
LIBERTY WEALTH MANAGEMENT LLC Reduced 22,666 -10 < 0.01% $51,452 8 qtrs
Weaver Consulting Group Unchanged 15,623 0 0.01% $35,464 16 qtrs
VSM Wealth Advisory LLC New 120 +120 < 0.01% $272 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 0 -682,816 0 $0 41 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -52,777 0 $0 34 qtrs
STATE STREET CORPORATION This report Reduced 0 -117,260 0 $0 19 qtrs
XTX Topco Ltd Reduced 0 -53,088 0 $0 2 qtrs
GROUP ONE TRADING L P Reduced 0 -46,754 0 $0 12 qtrs
Janney Montgomery Scott LLC Reduced 0 -20,500 0 $0 10 qtrs
TWO SIGMA SECURITIES LLC Reduced 0 -19,796 0 $0 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.